Alpha memo: resveratrol exercise training cross-context signal

Artifact

Agent-certified evidence map from agent-v6-alpha-eval-20260626230706

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Add a brief note explicitly stating that this memo is not a clinical or policy recommendation and should not be used to guide supplementation decisions, reinforcing the bounded alpha-memo scope.
2. Consider tightening the 'Why this is surprising' framing to remove any implication that a within-study comparison was attempted, making the cross-species inference character even more explicit.
3. Optionally, add one sentence on what a minimal next-step study design would look like (already partially captured under falsifiers) to strengthen the gaps dimension.

Minor issues

• Receipt 1 description mentions the excerpt is truncated and mechanistic Nrf2/FTH1/GPX4 confirmation is title-only; the memo is appropriately transparent but could briefly note what the excerpt does confirm (inflammatory factors, intestinal permeability) versus what is title-only (the full mechanistic axis).
• The phrase 'raising the possibility — not directly tested within either study — that the same molecule can be helpful in one context and unhelpful in another' is well-hedged but slightly editorial; could be tightened to 'raises a cross-context question' to maintain neutrality.
• The 'Why this is surprising' heading could be softened to 'Why this is a cross-context signal' to better match the bounded scope.

Reviewer note

This is a competent, bounded alpha-memo that honestly maps a two-receipt cross-context signal for resveratrol in exercise contexts. The title/topic (resveratrol + exercise training cross-context) matches both cited receipts cleanly: Receipt 1 is a mouse intestinal protection study with Nrf2/FTH1/GPX4 mechanistic framing (2023, Turk J Med Sci), and Receipt 2 is the Gliemann et al. 2013 J Physiol human RCT showing blunted cardiovascular training response in aged men. No title/source misalignment. The memo is admirably transparent about the cross-species, cross-dose, cross-tissue, cross-endpoint heterogeneity between the two receipts and refuses to claim a clean species- or age-driven split, instead labeling it a 'heterogeneous cross-context signal.' Limitations are specific and material (truncated excerpt for Receipt 1, small n=27 for Receipt 2, multiple confounded axes between the two studies). The falsifier section proposes a concrete human replication design. Claims stay proportionate: 'may produce context-dependent signals' is appropriately hedged and matches the receipt-level evidence. Source grounding is strong — both DOIs match supplied excerpts that confirm species, dose, duration, and key endpoints. Synthesis is coherent: the two receipts are integrated into a single bounded alpha-signal rather than listed separately. The only reason this is revise rather than accept is that minor framing polish and a clearer clinical/policy non-recommendation note would harden the artifact without changing its substance.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: fallback_tiebreak_failed_conservative

Prompt: reviewer-v11-research-synthesis